logo

For the Inventor, By the Inventor

San Mateo, CA, United States of America

Irene Chen

This inventor holds 5 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignee: Gilead Sciences, Inc.. Active years: 2017-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Irene Chen. Retrieved from https://idiyas.com/inventor/irene-chen-v80qljmz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 57(Granted Patents)


Company Filing History:

goldMedal5 out of 946 
 
Gilead Sciences, Inc.
 patents

Years Active: 2017-2021

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents
1. 11202780 - Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide (2021-12-21),
2. 10385067 - Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate (2019-08-20),
3. 10098886 - Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide (2018-10-16),
4. 9708342 - Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate (2017-07-18),
5. 9682084 - Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide (2017-06-20),

Title: Irene Chen: Innovator in Pharmaceutical Chemistry

Introduction

Irene Chen is a prominent inventor based in San Mateo, California. She has made significant contributions to the field of pharmaceutical chemistry, holding a total of 5 patents. Her work focuses on the development of novel crystalline forms and pharmaceutical formulations that have therapeutic applications.

Latest Patents

Irene's latest patents include innovative crystalline forms of complex compounds. One notable invention is related to crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide. This invention encompasses pharmaceutical formulations and their therapeutic uses. Another significant patent involves sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I, which is aimed at treating or preventing HIV infections.

Career Highlights

Irene Chen is currently employed at Gilead Sciences, Inc., where she continues to advance her research in pharmaceutical innovations. Her work has been instrumental in developing new treatments that address critical health issues.

Collaborations

Irene collaborates with esteemed colleagues, including Ernest A Carra and Vahid Zia, to further enhance the impact of her research and inventions.

Conclusion

Irene Chen is a trailblazer in the field of pharmaceutical chemistry, with a focus on innovative solutions for health challenges. Her contributions through patents and collaborations highlight her commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…